Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. by Blencowe, Hannah et al.
Blencowe, H; Lawn, JE; Vazquez, T; Fielder, A; Gilbert, C (2013)
Preterm-associated visual impairment and estimates of retinopathy of
prematurity at regional and global levels for 2010. Pediatric research,
74 Suppl 1. pp. 35-49. ISSN 0031-3998 DOI: 10.1038/pr.2013.205
Downloaded from: http://researchonline.lshtm.ac.uk/1440256/
DOI: 10.1038/pr.2013.205
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-sa/2.5/
ArticlesPopulation Studynature publishing group
Background: Retinopathy of prematurity (ROP) is a leading 
cause of potentially avoidable childhood blindness worldwide. 
We estimated ROP burden at the global and regional levels to 
inform screening and treatment programs, research, and data 
priorities.
Methods: Systematic reviews and meta-analyses were 
undertaken to estimate the risk of ROP and subsequent visual 
impairment for surviving preterm babies by level of neonatal 
care, access to ROP screening, and treatment. A compartmen-
tal model was used to estimate ROP cases and numbers of 
visually impaired survivors.
results: In 2010, an estimated 184,700 (uncertainty range: 
169,600–214,500) preterm babies developed any stage of ROP, 
20,000 (15,500–27,200) of whom became blind or severely 
visually impaired from ROP, and a further 12,300 (8,300–18,400) 
developed mild/moderate visual impairment. Sixty-five per-
cent of those visually impaired from ROP were born in middle-
income regions; 6.2% (4.3–8.9%) of all ROP visually impaired 
infants were born at >32-wk gestation. Visual impairment from 
other conditions associated with preterm birth will affect larger 
numbers of survivors.
conclusion: Improved care, including oxygen delivery and 
monitoring, for preterm babies in all facility settings would 
reduce the number of babies affected with ROP. Improved data 
tracking and coverage of locally adapted screening/treatment 
programs are urgently required.
in 2010, an estimated 19 million children were visually impaired (1), having substantial effects on the individual, 
family, and society (2). Children born preterm are at greater 
risk of visual impairment than their term-born peers. Even 
without manifest neurological complications, e.g., periven-
tricular leukomalacia, intra- or periventricular hemorrhage, 
or optic atrophy, preterm birth removes the visual system 
from the nurturing intrauterine environment during a period 
of rapid maturation and hence increases the risk of reduced 
visual function (Table 1 and Figure 1) (3).
Retinopathy of prematurity (ROP) is the most widely rec-
ognized cause of visual impairment after preterm birth and is 
defined as a vision-threatening disease associated with abnor-
mal retinal vascular development at the boundary of vascular-
ized and avascular peripheral retina (Table 2) (4). Babies who 
are most preterm or have associated neonatal morbidity, e.g., 
respiratory distress syndrome, infection, poor weight gain, and 
hyperglycemia, are at the greatest risk of ROP (5,6). Oxygen plays 
a critical role in this process, with both hypoxia and hyperoxia 
affecting levels of growth factors, such as vascular endothelial 
growth factor, essential for normal retinal vascular develop-
ment. Hence, rates of ROP are dependent on the quality of care 
received, including oxygen delivery, with continuous monitoring 
to maintain safe oxygen saturation levels (7). Most cases of ROP 
are mild and resolve spontaneously without treatment. A small 
proportion progress to more severe ROP, which, if untreated, can 
result in retinal detachment or scarring and distortion of the ret-
ina, which are usually associated with irreversible vision loss (8).
ROP was first recognized as an important cause of blindness 
in high-income countries in the 1940s and 1950s when survival 
rates of very-low-birth-weight babies “<1,500 g” or approxi-
mately <32-wk gestation were improving in association with the 
widespread use of unrestricted oxygen supplementation. This 
has been termed the first ROP epidemic, which affected moder-
ately preterm babies in high-income countries. Restricting the 
use of oxygen reduced blindness from ROP but increased mor-
tality and the risk of cerebral palsy (9). The double-edged sword 
of supplemental oxygen has, therefore, been known for many 
years, and oxygen is now known to be associated with other 
morbidities in preterm infants, including bronchopulmonary 
dysplasia and periventricular leukomalacia (10).
Since the 1970s, extreme prematurity has been the domi-
nant driving factor of ROP in high-income countries, with 
most cases being in the most preterm, i.e., gestational age 
(GA) < 28 wk babies. This is termed the second ROP epidemic. 
Increasing survival at lower GA has caused this second epi-
demic to persist, stimulating new developments in methods 
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of detecting potentially blinding ROP and new treatments 
(Table 2). However, even in high-income settings, there is wide 
variation in the reported rates of ROP between neonatal inten-
sive care units (NICUs), even after adjusting for case mix, which 
may be explained by differences in the quality of care including 
varying approaches to oxygen saturation targets and monitor-
ing (11,12). In the early 1990s, an emerging epidemic of blind-
ness in children in low- and middle-income (LMI) countries 
(LMIC) due to ROP was recognized, initially detected by exam-
ining children in schools for the blind in Chile (13). Recent 
studies suggest that ROP is an increasingly important cause of 
avoidable blindness in China, Southeast and South Asia, Latin 
America, and parts of Eastern Europe (14–16).
Previous estimates derived using data from schools for the 
blind together with blindness prevalence estimates suggested 
that at least 50,000 children aged up to 15 y are blind from 
ROP globally, with the highest proportion and numbers being 
in Latin America (17). The recent Global Burden of Disease 
estimated that 257,000 (uncertainty range: 154,000–376,000) 
years lived with disability worldwide in 2010 were associated 
with visual impairment secondary to ROP, but the methods 
and inputs are yet to be published (18).
This article presents the first systematic regional and 
global estimates of the incidence of ROP and visual loss from 
ROP for 2010. We discuss other adverse visual outcomes 
associated with preterm birth, and finally, we consider the 
table 1. Long-term visual complications following preterm birth 
Structural changes  ROP ROP is a relatively common complication following very preterm birth. It is associated with long-
term adverse visual outcomes and is discussed in detail in this article.
 Refractive errors Preterm babies are born myopic (near-sighted) due to a shallow anterior chamber, increased 
corneal curvature, and a spherical lens. They are at increased risk of persistent myopia due to 
arrested development of the anterior segment, resulting in an eye with low axial length to power 
ratio, a shallow anterior chamber, and a thick lens, even in the absence of ROP (68,69).
 Strabismus Babies born preterm are at increased risk of strabismus, with up to 13.5% of those <1,500 g 
affected (70,71), rising to more than 50% in severe ROP (72). Preterm birth is one of the 
commonest factors associated with strabismus at a population level (73).
Functional outcomes  Visual acuity Up to 50% of babies with a birth weight of <1,500 g may suffer from visual dysfunction in late 
childhood and these range from the subtle to severe, even blindness (68).
  Contrast 
sensitivity
Reduced contrast sensitivity has been reported in preterm populations with no ROP or other 
known neurological abnormalities (74). This is important in reading ability and may account for 
some of the increased school learning impairment in preterm infants.
 Visual field defects Visual field defects associated with retinal (including treatment for ROP) or visual pathway 
(including intraventricular hemorrhage) factors have been reported (75).
 Color vision An increased prevalence of color deficits, especially of the blue–yellow type has been reported (76).
 Perception Problems with recognition, orientation, depth perception, and perception of movement are 
common (77).
Babies born preterm are at increased risk of long-term visual problems due to the combination of the removal of the visual system from the nurturing intrauterine environment during 
a period of rapid maturation and an overall immaturity, leading to localized complications, e.g., ROP, and neurological complications, e.g., cerebral vision impairment due to intracranial 
complications. This risk is highest in the most preterm babies, but even moderate prematurity of 32–36 wk gestation is associated with an increased risk of visual morbidity (78).
Figure 1. Disease schema for visual impairment after preterm birth.
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programmatic importance of these findings and how to 
improve the data.
Methods
The definitions used in this article are described in Table 3. Table 2 
provides details of the system used to classify ROP and the indications 
for and methods of treatment for ROP, which have changed over time. 
Many individuals blind from ROP will have other associated neuro-
developmental impairments. In addition to the total burden of ROP, 
we quantified the estimated number of children blind or severely visu-
ally impaired from ROP without neurodevelopmental coimpairment.
Data Searches and Inputs
A systematic literature review was undertaken of the main online 
literature databases, including Pubmed/Medline, Embase, CAB 
abstracts, Popline, Web of Science, Cumulative Index to Nursing 
and Allied Health Literature, Latin American and Caribbean 
Literature on the Health Science “LILACS,” and WHO Regional 
library databases, applying the general search strategy described in 
the Methods article of this supplement (19). Search terms included 
multiple variants of terms covering the following areas “ROP” and 
“incidence/prevalence” or “screening” or “morbidity” or “visual 
impairment/blind/myopia”. Medical subject heading terms were 
used when available (see Supplementary Information online for 
full details of search terms, dates, and inclusion criteria). Snowball 
searching of reference lists was used to identify further studies of 
interest. Further searches of statistical databases, including EURO-
PERISTAT country-based neonatal network reports, were under-
taken. Data were abstracted if the study fulfilled the inclusion crite-
ria, regardless of the year of birth of the cohort. In view of the rapid 
changes and progress in neonatal intensive care in low-mortality 
settings during the past decades, especially for the preterm baby, 
only studies with birth cohorts with a median year of 2000 or later 
were included in the main analysis.
Standard meta-analysis techniques were used to obtain summary 
estimates of the parameters of interest, including neonatal case fatality 
risks, risk of ROP (by GA and access to care), and risk of visual impair-
ment in those with ROP (by level of care and access to screening and 
treatment; Figure 2). Heterogeneity across studies was assessed using 
the I2 and the χ2 test. Where evidence of heterogeneity was present 
(I2 > 70% or P < 0.05), a random-effects meta-analysis model was used.
Overview of Modeling Approach
A three-step compartmental model was constructed, using the estimated 
input parameters, to estimate visual impairment attributable to ROP 
among survivors of preterm birth (Figure 2). In step 1, we estimated the 
prevalence of preterm birth among live births; in step 2, the number of 
babies born preterm who received neonatal intensive care and survived 
(postneonatal survivors at risk of ROP) was estimated; and in step 3, 
we estimated that the number of these survivors who were estimated to 
have ROP and the number of those affected who are visually impaired, 
which is screening and treatment dependent. These steps were applied 
in sequence for the live births in each country with more than 10,000 
births for the year 2010 (20). All results are presented at the regional level 
using the Global Burden of Disease superregional grouping (19).
We calculated a quantitative assessment of the uncertainty sur-
rounding these estimates using a statistical approach based on the 
compartmental model, taking 1,000 random draws at each step, 
assuming a normal distribution with mean equal to the point esti-
mate of the parameter and the SD equal to the estimated SE of the 
parameter. We summed the data for each draw at the worldwide or 
regional level depending on the data input pooling level and present 
the 2.5th and 97.5th percentiles of the resulting distributions as the 
uncertainty range.
results
The parameters and process of each step are detailed with a 
short summary of the results. Searches for the prevalence of 
preterm birth– and gestation-specific case fatality rate yielded 
12,828 titles and abstracts, 792 of which were included. For 
the ROP-specific parameters, including incidence, risk of 
visual impairment, and neurodevelopmental comorbidity, 
3,791 titles and abstracts were reviewed, and 80 studies were 
included (see Supplementary Information online). A sum-
mary of the parameter values used is shown in Table 4 (see 
also Supplementary Information online). A summary of the 
regional results is given in Table 5.
table 2. Classification, screening, and treatment of ROP 
Classification The importance of classification is to predict which babies are most at risk of progression to vision-threatening disease and to 
intervene in a timely manner. The current classification has several components: 
location or “zone” (1, 2, or 3): three concentric circles centered on the optic disc are used to describe the anteroposterior 
location of the ROP, which develops at the junction between vascularized and avascular retina. ROP in zone 1, which is the 
circle nearest the optic disc, carries the worst prognosis. Severity: “stage” classified from 1 (demarcation line only) to 5 (total 
retinal detachment). 
Presence of “plus disease” indicating dilatation and tortuosity of the retinal vessels (severer disease (79)), or  “pre-plus” disease 
(intermediate severity). 
Extent: clock hours of ROP along the circumference of the junction between vascularized and avascular retina. 
“Aggressive, posterior ROP” denotes a more virulent, rapidly progressing form of ROP. In high-income countries, this is seen 
only in the extremely preterm. However, it has been reported in bigger babies in other settings, especially where babies 
receive unblended oxygen (80).
Screening ROP is a highly predictable condition, with both onset and progression of ROP governed by postmenstrual and not postnatal 
age (81), with a slight hastening of ROP onset in the most immature infants (82) and compression of its clinical course reported 
in larger infants of >33 wk GA. Treatment rarely is required before 31-wk PMA (40). Mean age for treatment in high-income 
settings is 35.2 wk PMA (range: 30.6–42.1 wk) (4). In low-income settings with later case detection, treatment may be required 
up to 51 wk PMA (40). Screening those most at risk and treating if the ROP progresses to a sight-threatening level is standard 
care to prevent serious visual disability.
Treatment The first treatment trial (CRYO-ROP) involved peripheral retinal cryotherapy to eyes with a constellation of clinical signs 
called “threshold ROP” (i.e., at least five continuous or eight cumulative clock hours of stage 3 ROP in zones 1 or 2, in the 
presence of “plus” disease—engorgement and tortuosity of the retinal and iris blood vessels), which untreated had a 50% 
risk of progression to retinal detachment. This trial was highly effective, halving the rate of progression (83). Since then, laser 
treatment has become the preferred option, giving better results and fewer complications. The current treatment guidelines 
are based on the findings of a further trial (ETROP) that compared treatment at early stages of disease (called type 1 ROP) with 
treatment at threshold disease, demonstrating that earlier treatment gives better outcomes in terms of both structure and 
function. Type 1 ROP is defined as zone 1: stage 3, or stage 1 or 2 with plus disease; or zone 2: stage 2 or 3 with plus disease (4).
PMA, postmenstrual age; ROP, retinopathy of prematurity.
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Step 1: Preterm Live-Birth Prevalence
Preterm live-birth prevalence. National preterm birth rates 
for 2010 were estimated using two regional multilevel statis-
tical models including data from national registries or statis-
tical offices, Reproductive Health Surveys, unpublished data, 
and published articles identified through a systematic review. 
These included 738 reported data inputs from 99 countries; 
the majority (547/738) of the data available were from high-
income countries. Full details of the searches, methodol-
ogy input data, and results have been published elsewhere, 
including the estimates for 2010 for 184 countries and time 
trends for 65 countries (21).
GA subdivisions. The distribution of preterm births by GA 
subgroup was based on a meta-analysis of 345 data points (131 mil-
lion live births (21)). The pooled estimate from these studies shows 
that of all preterm births, 5.2% (95% confidence interval (CI): 5.1–
5.3%) were at less than 28 wk GA, 10.4% (95% CI: 10.3–10.5%) were at 
28–31 wk, and 84.3% (95% CI: 84.1–84.5%) were at 32–36 wk. Eighty-
five percent of births at 32 wk or more were in the range of 34–36 wk.
table 3. Definitions for visual impairment after preterm birth 
Grading Brief definition/explanation
ICD-10 codes 
and categoriesa
Retinopathy of 
prematurity
See text for 
details
A vision-threatening disease associated with abnormal retinal vascular development in 
the incompletely vascularized retina of preterm babies.
H35.11–H35.17
Amblyopia A unilateral or bilateral decrease of visual acuity caused by deprivation of pattern vision 
(e.g., cataract) or abnormal binocular interaction (e.g., strabismus), for which no cause 
can be detected and may in some cases be reversed by therapeutic measures (84).
Strabismus A misalignment of the eyes, which if uncorrected can lead to failure to develop 
binocular vision and amblyopia.
H50
Myopia “Near-sighted.” Eyes have too much optical power, or the eye is effectively too long, 
leading to blurred vision as the image is focused in front of the retina.
H52.1
Hypermetropia “Far-sighted.” Eyes do not have enough optical power, or the eye is effectively too short, 
leading to blurred vision as the image is focused behind the retina.
H52.0
Visual impairment  Mild Visual acuity from <6/12 (<20/40) to ≥6/18 (≥20/60) H54 codes
 Moderate Visual acuity from <6/18 (<20/60) to ≥6/60 (≥20/200)
 Severe Visual acuity from <6/60 (<20/200) to ≥3/60 (≥20/400)
 Blind Visual acuity less than <3/60 (<20/400) 
aICd =  International Classification of diseases 10th revision.
Figure 2. Compartmental model: parameters required and methods for estimation of the global burden of visual impairment due to retinopathy of 
prematurity.
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Prevalence estimates. We previously estimated that globally 
14.9 million babies (uncertainty range: 12.3–18.1 million) were 
born preterm in 2010 (Table 5). Approximately 0.8 million 
(0.7–0.9 million) were of GA <28 wk, 1.6 million (1.5–1.7 mil-
lion) were 28–31 wk, and 12.6 million (12.3–14.0 million) were 
32–36 wk (21).
table 4. Countries (184) according to level of neonatal mortality, showing the variation in input data for the estimation of the global burden for 
visual impairment after retinopathy of prematurity around the year 2010 
Countries according to level of NMR in 2010
NMR < 5: level 1 NMR 5 to <15: level 2 NMR ≥ 15: levels 3/4/5
Number of countries 46 62 76
Number of live births 13,260,651 40,270,948 81,147,584
ST
EP
 1
Preterm birth (<37 wk) 
prevalence data  
(per 100 live births)
30 countries,  
415 data sets, 
 N (preterm births) = 10,969,999,  
data range: 4.1–16.4%,  
median: 6.8%
28 countries,  
187 data sets,  
N = 5,185,520,  
data range: 3.1–19.5%,  
median: 5.9%
41 countries,  
136 data sets, 
 N = 1,927,074,  
data range: 3.5–28.5%, 
median: 8.5%
ST
EP
 2
Case fatality rate in first 28 
d among preterm babies 
receiving neonatal intensive 
care unit care (per 100 live 
births by gestational age 
group)
21 countries,  
36 data sets, 
 N (preterm births) = 388,253.  
Pooled estimate:  
<28 wk = 28.3%  
(95% CI: 25.4–31.2%);  
28–31 wk:  
5.8%  
(95% CI: 5.1–6.5%). 
32–36 wk, assume no ROP in babies 
≥32 wk in 2010 in NMR 1 settings.
12 countries,  
17 data sets, 
 N = 5,379.  
Pooled estimate:  
<28 wk = 51.7%  
(95% CI: 43.3 – 69.0%);  
28–31 wk:  
NMR 5 to <15: 15.3%  
(95% CI: 9.9–20.6%);  
NMR ≥15: 28.8%)  
(95% CI: 25.2–32.5%),  
32–36 wk = 6.1%  
(95% CI: 1.4–10.9%)
ST
EP
 3
Incidence of any ROP in 
survivors after preterm birth
17 countries,  
13 data sets.  
Pooled estimate:  
all <32 wk = 21.8%  
(95% CI: 16.6–27.0%). 
32–36 wk assume none
23 countries,  
42 data sets.  
Pooled estimate:  
all <32 wk = 36.5%  
(95% CI: 31.8–41.1%). 
32–36 wk = 7.7% (95% CI: 6.7–8.7%)a
Risk of progression to level 
at which treatment would be 
given (prethreshold/type 1 
disease)
SWEDROP study  
(62); <32 wk = 18.1%  
(95% CI: 14.5–21.8%). 
32–36 wk assume none
4 countries, 4 data sets;  
<32 wk = 36.4% 
(95% CI: 14.8–58.0%). 
2 countries, 2 data sets; 32–36  
wk = 10.8% (95% CI: 2.7–18.8)
Risk of progression to 
threshold level if not treatedb
ETROP study (27); 
 <32 wk = 66.4% of those reaching 
prethreshold and remaining untreate d, 
i.e., % of 12% all ROP. 
32–36 wk assume none
12 countries, 17 data sets;  
<32 wk =28.2%  
(95% CI: 20.4–35.9).  
4 countries, 5 data sets; 
32–36 wk = 10.5% (95% CI: 7.2–13.9)
All NMR levels
Visual impairment in those with 
severe ROP
Without treatmentc                     With treatmentd
Mild impairment: 3% (95% CI: 2–6%)        Mild visual impairment: 14% (95% CI: 9–40%)
Moderate impairment: 10% (95% CI: 7–15%)  Moderate impairment: 26% (95% CI: 22–32%)
Severe impairment: 12% (95% CI: 8–17%)     Severe impairment: 16% (95% CI: 17–25%)
Blind: 47% (95% CI: 41–54%)                Blind: 9% (95% CI: 6–13%)
Coimpairment with 
neurodevelopmental 
impairment in babies with 
visual impairment due to ROP
5 countries,  
10 data sets,  
N (visually impaired survivors) = 555. 
Pooled estimate = 54.9%  
(95% CI: 38.0–71.7%)
aSingle study by Zin et al. has screened all neonatal intensive care unit admissions from 32 to <37 wk GA (51). Thirteen studies were very heterogeneous, with large variations in those 
admitted in this group who were screened. Pooled estimate (13.4% (10.4–16.4%)) (see Supplementary Information online). bNo difference in rates of progression to threshold disease 
between studies in NMR 2 and 3 countries, so result pooled across these was used. cIn those reaching threshold and not treated (CRYO-ROP control arm) (8). dIn those reaching type 1 
level (prethreshold; eTROP treatment arm) (4).
ROP, retinopathy of prematurity.
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Step 2: Calculation of the Number of Postneonatal Survivors at 
Risk of ROP
Coverage and quality of care. Data were not available to esti-
mate every parameter individually for each country. To over-
come this, we used neonatal mortality rate (NMR) as a proxy 
for the proportion of neonatal units with an ROP program 
and the quality of newborn care, classifying countries into 
three categories (Table 4) (19).
Defining the population at risk of ROP. For the purpose of 
these estimates, we assumed that only babies with access to 
NICU would be at risk of ROP, with high-intensity neonatal 
care defined as a minimum of the following: availability of ven-
tilatory support, ability to deliver and monitor oxygen satura-
tions, and high nurse-to-patient ratios). However, babies cared 
for in lower-level facilities, e.g., special care baby units in low-
resource settings, may also be at risk, especially if receiving 
unmonitored oxygen; however, insufficient data are available to 
quantify this risk. To be consistent with previous work on cover-
age of care around the time of birth, we used coverage assump-
tions based on facility birth coverage as in the Lives Saved Tool 
(22). We undertook a literature- and Web-based search to iden-
tify LMICs with data on the number of neonatal intensive care 
cots to inform these assumptions, assuming a requirement of 
approximately one NICU cot per 1,000 live births (19).
In high-income countries, with good- to high-quality NICU 
care, ROP is currently only seen in babies with GA < 32 wk at 
birth (23). We therefore assumed that no baby of more than 
32-wk gestation would be at risk in these settings. In LMI set-
tings, substantial variation in the quality of NICU care exists, 
especially in terms of ventilatory support and oxygen-moni-
toring practices. Maturer preterm babies born at 32–36 wk are 
also at risk of ROP in these settings (24,25). Hence, the popula-
tion at risk was defined as babies surviving NICU care with GA 
< 32 wk in all settings and babies surviving NICU care with GA 
32–36 wk in countries with an NMR of >5 per 1,000 live births.
Gestation-specific case fatality rate by NMR group among those 
admitted to NICU care. For low-mortality countries (NMR < 
5), GA-specific neonatal mortality data were abstracted from 
cohort studies identified from searches, predominantly from 
NICUs, which included the great majority of live-born babies 
less than 32-wk GA in these countries. Further searches of sta-
tistical databases, including EURO-PERISTAT and country-
based neonatal networks were used to provide population-
based data from countries with more advanced data-reporting 
systems. Case fatality risks were estimated as 28.3% (95% CI: 
25.4–31.2%) for those <28 wk GA and 5.8% (95% CI: 51.0–
65.0%) for 28–31 wk (Table 4).
For higher-mortality countries (NMR ≥ 5), 17 studies of 
mortality in babies <28 wk with access to NICU were iden-
tified. No strong evidence of a difference in mortality for 
babies <28 wk was found between NMR 5 to <15 and NMR 
≥ 15 countries (P < 0.05), and the pooled estimate of 51.7% 
(95% CI: 43.3–60.0%) was used for all babies with access to 
NICU in countries with NMR ≥ 5. For babies 28–31 wk with 
access to NICU care, the pooled estimated mortality was 
15.3% (95% CI: 9.9–20.6%; 10 studies) in NMR 5 to <15 and 
28.8% (95% CI: 25.2–32.5%; 5 studies) in NMR ≥ 15 coun-
tries. For babies 32–36 wk GA admitted to NICU, only one 
study reporting neonatal mortality was available. This study 
from Nepal (NMR ≥ 15) suggested a mortality of 6.1% (95% 
CI: 1.4–10.9%) in this group (26).
Estimates of the number of deaths and postneonatal survivors 
at risk of ROP. A total of 666,600 (28.5% (uncertainty range: 
662,900–719,600)) of those born preterm at <32 wk are esti-
mated to have received NICU care, 168,000 (153,900–193,500) 
of whom died during the first month of life. Moreover, 498,600 
(487,200–547,700) are estimated to have survived the neonatal 
period, being at risk of ROP. In addition, an estimated 372,500 
(329,400–397,100) babies born at 32 to <37 wk in LMICs 
received NICU care, 349,800 (329,400–397,100) of whom 
survived the first month of life. A total of 848,300 (838.400–
924,700) surviving babies are estimated to have been at risk of 
ROP-associated visual impairment in 2010 (Table 5).
Step 3: Calculation of the Number of Babies With ROP and With 
Associated Visual Impairment
The precise risk was determined by GA and quality of care 
received using pooled risk from studies across the same NMR 
banding as a proxy of quality of neonatal intensive care.
Gestation-specific risk of any ROP by NMR group. The pooled 
estimate from studies reporting population-based incidence 
of ROP from 2000 to 2010 suggested that 21.8% (95% CI: 
16.6–27.0%; 13 studies) of all survivors <32-wk GA in coun-
tries with NMR < 5, and 36.5% (95% CI: 31.8–41.4%; 42 
studies) in countries with NMR ≥ 5 developed some degree 
of ROP (Figures 3 and 4).
Coverage of screening. The visual outcome after ROP is depen-
dent on the severity of ROP and access to screening and treat-
ment. Screening detects stages of ROP that have a high risk 
of progression to the blinding stages so that treatment can be 
given to reduce the risk of lifelong visual impairment. Limited 
data were available on coverage of screening in all settings. 
In countries with NMR < 5, it was assumed that coverage of 
screening would be near universal and that 95% of those <32 wk 
GA would be screened. In NMR 5 to <15 countries, coverage of 
screening was more variable, and it was assumed that 40% of 
those at risk in NMR 5 to <15 countries and 20% of those in 
countries with NMR ≥ 15 would be screened based on expert 
opinion.
Risk of progression to type 1 disease and requiring treatment in 
those with ROP. We assumed that 18.1% (95% CI: 14.5–21.8%) 
of those with any ROP would progress to type 1 prethreshold 
disease requiring treatment in NMR < 5 settings based on one 
large population-based study from Sweden (23). For settings 
with NMR ≥ 5, we used a pooled estimate from four studies 
suggesting that 36.4% (95% CI: 14.8–58.0%) of those <32 wk 
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with ROP and 10.8% (95% CI: 2.7–18.8%) of those ≥32 wk 
would progress to type 1 disease (Table 4).
Risk of visual impairment in those receiving treatment for 
type 1 disease. With treatment, it was assumed that 25% (95% 
CI: 23–28%) of children would be blind or have severe visual 
impairment in all settings, with an additional 40% (95% CI: 
31–72%) having milder visual impairment based on the out-
come data from the intervention arm in the ETROP trial (27).
Risk of developing threshold disease in those with untreated 
type 1 disease. Natural history information on visual outcome 
in those with ROP and no access to treatment was only avail-
able from studies reporting outcomes of those with “threshold” 
and not “type 1” disease. Therefore, the proportion of those 
with type 1 disease who progress to threshold level if untreated 
was required. Based on the ETROP trial, 66.4% of those with 
type 1 disease and no treatment in NMR < 5 countries would 
develop “threshold disease” (4). The risk is likely to be greater 
in countries with NMR ≥ 5 with more variable quality of neo-
natal care. A pooled estimate suggested that 28.2% (95% CI: 
20.4–35.9%) of those <32 and 10.5% (95% CI: 7.2–13.9%) of 
those 32–36 wk GA with any ROP would develop threshold 
disease.
Risk of visual impairment in those with untreated threshold 
disease. Using data on rates of visual impairment follow-
ing untreated threshold disease from the control arm of the 
CRYO-ROP trial, we assumed that 59% (95% CI: 49–71%) of 
those not receiving treatment would have a severe adverse out-
come, with an additional 13% (95% CI: 9–21%) having milder 
visual impairment (Table 4) (28). These are similar to other 
natural history data findings (6,29).
Associated neurodevelopmental comorbidity. Ten studies 
were identified quantifying the risk of associated neurode-
velopmental impairment in ROP-affected visually impaired 
survivors of preterm birth. These suggested that 54.9% (95% 
CI: 38.0–71.7%) of visually impaired survivors with ROP had 
associated neurodevelopmental impairment. We have applied 
this rate to survivors in all regions; however, all 10 studies were 
undertaken in high-income settings where the majority of 
these babies would be extremely preterm and hence at high 
risk of neurodevelopmental impairment. In settings where 
survival rates among extremely preterm babies are low, and 
ROP occurs in relatively more mature babies, rates of associ-
ated neurodevelopmental impairment may be lower.
Estimates of the number of impaired survivors. We estimate 
that 184,700 (uncertainty range: 169,600–214,500) preterm 
babies worldwide developed some degree of ROP in 2010, 
26,900 (23,700–32,400) of whom were born at 32–36 wk GA. 
53,800 (28,800–85,000) of these babies developed potentially 
vision-impairing severe disease, requiring treatment, but 
only 22,700 (42%; (13,800–33,700)) of these babies received 
treatment.
An estimated 32,300 (24,800–44,500) preterm survivors in 
2010 suffered from long-term visual impairment secondary to 
ROP: 20,000 (15,500–27,200) with severe visual impairment 
or blindness and a further 12,300 (8,300–18,400) with mild 
or moderate visual impairment. Worldwide, only 6.2% (2,000 
(1,400–2,900)) of those with visual impairment were born at 
Figure 3. Meta-analysis of 13 studies in 2000–2010 reporting incidence of any retinopathy of prematurity in babies <32-wk GA in countries with neona-
tal mortality rate < 5. See Supplementary Information online for full details of the included studies.
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32–36 wk GA. An estimated 55% of those with visual impair-
ment will have other associated neurodevelopmental impair-
ment (Table 5; Figures 5 and 6).
These global figures mask big regional differences: 36% of 
worldwide live births, 31% of preterm births, 39% of cases 
of neurodevelopmental impairment, 60% of ROP cases, and 
65% of visually impaired survivors in 2010 were estimated to 
occur in the predominantly middle-income regions of Latin 
America, East Asia/Pacific, and North Africa/Middle East 
(Figure 4). Worldwide, in 2010, 16% of survivors born at <32-
wk GA are estimated to have some degree of ROP, with 3% 
having associated visual impairment (Figure 6).
discussion
In 2010, 13.0 million (12.7–14.3 million) babies of the 15 mil-
lion born preterm are estimated to have survived the neo-
natal period (30). At least 184,700 (169,600–214,500) have 
some degree of ROP, with 53,800 progressing to potentially 
vision-impairing disease. The risk is greatest for the most 
premature survivors in every setting, who also have the high-
est risk of associated neurodevelopmental impairment (30). 
In high-income countries, both ROP and associated adverse 
neurodevelopmental outcomes are most common in babies of 
<26 wk gestation (23,31). However, in LMICs, these adverse 
outcomes are still common in relatively maturer preterm sur-
vivors at 28- to 31-wk gestation and above (25,31,32).
These estimates of visually impaired preterm survivors are 
likely to be conservative for a number of reasons. In the esti-
mates of ROP, we only included babies who were cared for 
in NICUs, which may result in a substantial underestimation 
of the total burden because it does not include sick babies 
in special care baby units, with no access to NICU, but who 
may have received unblended, unmonitored supplemental 
oxygen. In addition, these estimates do not include causes 
of visual impairment secondary to preterm birth that are not 
associated with ROP, including cerebral vision impairment.
Following the identification of unmonitored supplemental 
oxygen as a causal factor in the development of ROP in the 
1950s, it was anticipated that improvements in neonatal care 
and oxygen management would prevent visual loss from ROP. 
However, although this reduced the disease in those moder-
ately preterm in high-income countries, blindness from ROP 
persisted, albeit at a low rate, especially among the increas-
ing number of extremely preterm (<28 wk) survivors (33). 
Figure 4. Meta-analysis of 42 studies in 2000–2010 reporting incidence of any retinopathy of prematurity in babies <32 wk admitted to neonatal inten-
sive care units in countries with neonatal mortality rate ≥ 5. See Supplementary Information online for full details of the included studies.
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Widespread introduction and refinement of screening proto-
cols to include those most at risk of visually impairing disease 
and timely treatment has further reduced the burden in high-
income countries, despite the increasing number of extremely 
preterm survivors. However, even in urban settings in LMICs 
with increasing provision of NICUs, awareness of ROP as a 
possible vision-impairing disease is frequently lacking among 
those providing neonatal care (34). State-of-the-art ophthal-
mological and modern NICU equipments are increasingly 
available, especially in private facilities, but standards of neo-
natal care often remain low, and systematic programs to detect 
and treat babies with severe ROP are not yet in place in all 
NICUs. Consequently, many infants are becoming blind, hav-
ing never been screened or examined by an ophthalmologist. 
Figure 5. Regional burden of visual impairment from retinopathy of prematurity among preterm babies born in 2010 and surviving the neonatal period.
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Figure 6. Summary of retinopathy of prematurity and associated visual impairment outcomes for survivors of 15 million preterm births worldwide in 
2010.
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Many of these babies are relatively more mature (GA > 30 wk), 
as in the first epidemic in high-income countries, and much 
severe ROP should be both preventable and treatable in these 
settings (25,35). Some countries with improving human devel-
opment index ratings may have reversed this trend during the 
past decade, e.g., Poland (36).
Data Limitations
We were not able to quantify the risk of ROP in preterm babies 
outside of NICU settings, and this may include large numbers 
of cases. In many special care baby units in LMICs, oxygen 
is available and is given by different devices, some of which 
will expose the babies to unblended high-flow oxygen, placing 
them at even higher risk of ROP. Historically, blindness due 
to retrolental fibroplasia, as end-stage ROP was described at 
that time, principally affected infants with birth weights in the 
range 1,000–2,000 g who had received high levels of unmoni-
tored supplemental oxygen.
Many included studies were reports by ophthalmologists of 
babies they had examined, with few details on the total preterm 
population from which the cases arose. Data limitations, espe-
cially from LMI settings, required a simplistic model, grouping 
babies into two GA groups, <32 wk and 32–36 wk. However, this 
led to the exclusion of useful resources of incidence data from 
high-income countries, e.g., neonatal network reports, where 
screening policies for babies born at 30 and 31 wk gestation are 
variable. An increasing number of studies from LMIC recom-
mend wider screening criteria than those used in high-income 
countries, but these criteria are often not evidence based. It is 
likely that severe ROP in maturer, less-sick babies is still being 
missed because they are not included in screening programs.
The recommendation to lower the treatment level for 
ROP to type 1 prethreshold from threshold was changed 
after the findings of the Early Treatment for Retinopathy 
of Prematurity (ETROP) study in 2003 (37). In view of this 
recent recommendation, few data were available on the risk of 
long-term visual outcomes in those treated for type 1 ROP. We 
therefore used the ETROP study to estimate the risk of long-
term visual outcomes. This may overestimate the risk because 
the trial included a high proportion of babies with the severest 
type of ROP, “zone 1 disease,” who would be expected to have 
the poorest visual outcomes. Some very small recent studies 
have suggested that the risk in general NICU populations may 
be lower (38,39), and even with very severe aggressive poste-
rior ROP, that complete regression of the disease is possible in 
the majority of eyes with aggressive laser treatment (142/169) 
(40).
We have not adjusted for ethnicity in our model. Several 
studies have reported a lower risk of severe ROP in those from 
black African descent compared with the risk in other ethnic 
groups and a higher risk in Hispanics and those of south Asian 
descent (6,41–44).
Programmatic Implications and Future Developments
Prevention of ROP
Interventions before preterm birth. Much can be done to pre-
vent ROP, starting before preterm birth (Table 6). There is 
evidence that antenatal corticosteroids given within 48 h of 
preterm delivery promote lung maturation and reduce the risk 
of respiratory distress syndrome. This is likely to reduce these 
babies’ requirement for oxygen and hence reduce the risk of 
ROP due to the use of poorly controlled oxygen therapy (45). 
However, this simple inexpensive intervention has low cover-
age in LMI settings.
Improving quality of neonatal care. Care provided imme-
diately after birth, including prevention of hypothermia, 
 consideration of delayed cord clamping, minimizing lung 
damage by avoiding initial 100% oxygen, and early use of nasal 
continuous positive airway pressure can have a major impact 
table 6. Research in context regarding the burden of ROP 
Data findings Retinopathy of prematurity presents an important burden worldwide, with an estimated 185,000 babies affected in 2010 and 43,000 
visually impaired survivors. The proportion of affected babies is low in the lowest-income regions, notably sub-Saharan Africa, because 
of the excess mortality for preterm babies. The proportion is higher in middle-income regions because of increasing access to neonatal 
intensive care, with challenges in the quality of care. In high-income, low-mortality settings, the proportion of visually impaired babies 
is lower, probably related to improved quality of care (prevention) and systematic approaches to ophthalmological management and 
follow-up.
Data gaps and 
improvements
Major gaps were found in the quantity and the quality of data including geographic gaps, especially for low- and middle-income 
countries. Data on visual impairment need immediate prioritization for settings where neonatal intensive care is being scaled up. 
Challenges of data comparability over time with changes in classifications used to report ROP; reporting using birth weight versus 
gestational age criteria or eyes versus children; and in some cases, unclear population denominators. 
Actions/possible solutions: Ministries of Health to document which neonatal intensive care units have high-quality ROP programs; 
ophthalmologists to report findings of screening, treatment, and follow-up using standard formats and definitions; inclusion of ROP in 
routinely collected statistics, e.g., neonatal surveillance standard data set for all at-risk babies.
Data for action Key program priorities include the following: prevention of ROP; strategically addressing methods for the prevention of preterm 
birth and scaling up the use of antenatal corticosteroids in all settings, coupled with improving the quality of neonatal care, including 
infection prevention, and crucially ensuring optimal use of oxygen and making oxygen monitoring a standard of care in all facilities 
caring for preterm babies. Prevention of visual impairment: screening for all babies at risk of developing visual impairment from severe 
ROP, using locally validated screening criteria. Access to timely treatment, if required, to prevent adverse visual outcomes. Identification 
and care of survivors at risk of disability: routine follow-up of all with severe ROP. Correction of severe refractive errors or strabismus to 
prevent amblyopia and ensure optimal visual development. Early identification of blindness and severe visual impairment along with 
facilitation of educational and family support, including for those with associated neurodevelopmental disability.
ROP, retinopathy of prematurity.
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whether preterm babies should be routinely screened for visual 
impairment during childhood, even if they were not affected 
by ROP (7). Routine screening is not currently carried out in 
many settings, and increasing awareness among parents and 
teachers of the increased risk—and encouraging vision test-
ing if they have concerns—is important in all settings. Prompt 
treatment of strabismus and high refractive errors is required 
to prevent amblyopia and to promote normal development. 
Spectacles present a simple and affordable method of treating 
refractive errors associated with preterm birth but require fit-
ting and long-term follow-up so that the prescription can be 
changed as the child grows; moreover, repairing or replacing 
broken or lost spectacles also is essential (66). As blindness is 
associated with poor educational achievement, social isola-
tion, and poverty, particularly in LMICs (67), children with 
profound vision loss will also require assessment in low vision 
services, access to assistive devices, and appropriate placement 
and support in school to improve their independence and 
quality of life, and ensure a productive adulthood (66).
Conclusion
More than 30,000 preterm babies worldwide in 2010 are esti-
mated to be visually impaired due to ROP. Much of this burden 
is preventable with improved quality of neonatal care, nota-
bly oxygen monitoring, and with screening and treatment of 
vision-threatening ROP. Urgent action is required to improve 
awareness of ROP among all involved in the care of preterm 
babies, coupled with commitments to improve neonatal care, 
and to develop and implement national guidelines for the pre-
vention, detection, and treatment of ROP.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at http://
www.nature.com/pr
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on subsequent morbidity, including ongoing need for oxygen 
support (46). Optimal oxygen levels are required for preterm 
babies to maximize survival and minimize ROP, pulmonary 
morbidity, and disability (10). However, these optimal levels 
have not yet been determined. Two recent oxygen regulation 
trials have supported the benefit of targeting tight control of 
oxygen saturations in the range of 91–95%, with an increased 
risk of death with an 85–89% target (47,48); however, a third 
trial found no difference in death or disability at 18 mo between 
these two groups (49). A collaborative study group is currently 
conducting a meta-analysis of the full risks and benefits of 
these different oxygen targets (50). Until further evidence is 
available, the general conclusion is not to target levels less than 
90% (50), but because higher oxygen saturations in the range 
91–95% will increase the risks of ROP compared with lower 
targets of 85–89%, it is important to ensure that oxygen satura-
tions do not exceed the upper limit of 95%, especially in very 
preterm babies. Oxygen monitoring is routine in high-income 
countries, but variable in other settings, especially in units that 
are overcrowded and that lack both equipment and trained 
nursing staff in adequate numbers (51,52). A preliminary 
study from Peru suggests that severe ROP has declined since 
workshops were held for neonatal staff on how to improve the 
delivery and monitoring of oxygen (53). Infection increases 
the risk of ROP and should be minimized by strict adherence 
to infection control measures. Improving the quality of all 
aspects of neonatal care is required, with adequately equipped 
and staffed NICUs required to achieve this.
Prevention of Visual Impairment in Those Developing ROP
Screening for ROP. Implementation of locally adapted screen-
ing and treatment guidelines, alongside improvements in the 
quality of neonatal care, including optimal use and moni-
toring of oxygen, has minimized ROP-related blindness in 
high-income countries (54). However, even in well-resourced 
 settings with clear guidelines, actual practice and rates of 
ROP may vary substantially (55). Screening guidelines need 
to include a clear definition of the population at risk of visu-
ally impairing ROP, which will be location specific, but the 
reduced evidence base available from a specific location 
should be used only to broaden and not to narrow inclusion 
criteria. Some middle-income countries have developed local 
screening criteria guidelines (56).
The screening examination is associated with pain and stress 
for the babies, and unnecessary examinations have substan-
tial workload implications (57). Recent work in high-income 
countries has therefore focused on refining the screening pro-
tocols, e.g., using scores to detect those most at risk, to mini-
mize the number of examinations of babies at very low risk of 
visually impairing ROP (58).
Screening requires significant infrastructure investment, 
coordination, planning, skilled ophthalmologists, and team-
work (59). Standard screening examination by indirect oph-
thalmoscopy, a highly specialized procedure, is challenging 
in all settings, either due to a lack of specialist expertise or 
because it is not seen as an efficient use of ophthalmologists’ 
time because 39–55 examinations are required to detect a sin-
gle case needing treatment (60).
Digital imaging of the neonatal retina is used increasingly 
in ROP screening. Studies have shown that digital imaging 
has high accuracy and reliability and that it may be superior to 
indirect ophthalmoscopy in some situations and is less pain-
ful to the infant (61,62). Retinal findings can be viewed by the 
neonatal team and infant’s family, promoting greater under-
standing of the condition. Digital imaging has also provided 
the platform for telemedicine, which permits retinal images 
to be captured by either a trained technician, physician, or 
neonatal nurse and transmitted to an expert who may be a 
few miles or another country away, with successful telemedi-
cine networks in the United States, Germany, India, and New 
Zealand (54). Experience to date has shown that severe dis-
ease is not missed by digital imaging and is identified 1–2 wk 
earlier than by indirect ophthalmoscopy (54). A challenge in 
the use of telemedicine is that severe ROP needs to be treated 
within 48 h of detection, and many babies still need to be 
examined after discharge from the NICU (63). Mothers need 
to know at the time of examination/image capture whether 
their babies need treatment, whether they should come back 
for another examination, or whether they can be discharged.
The diagnosis of ROP is entirely visual, qualitative, and 
prone to error. Another anticipated development arising from 
digital imaging is the measurement and semiautomated analy-
sis of the vascular changes associated with ROP, i.e., plus dis-
ease. Several software systems have been developed, including 
Retinal Image multiScale Analysis, Computer-aided image 
analysis of the retina, and the ROP tool (54). To date, unfor-
tunately, all methods are slow, but they can detect plus dis-
ease and are better at measuring tortuosity than vessel width. 
However, it has been shown that vessel tortuosity close to the 
optic disc correlates well with ROP in the periphery (64).
Management of potentially vision-impairing ROP.  Laser pho-
tocoagulation, sometimes augmented by cryotherapy, is the 
current standard of care for severe ROP (Table 3). The treat-
ment destroys the hypoxic peripheral avascular retinal tissue, 
which produces the vascular growth factors that stimulate 
ROP. Despite treatment, visual acuity remains suboptimal in 
up to 60% of children (27). Newer treatments, e.g., anti–vas-
cular endothelial growth factor agents bevacizumab or ranibi-
zumab, for the severest disease may be promising, but there are 
concerns over their long-term systemic and ocular safety, and 
so, currently cannot be recommended for first-line treatment 
(65). Centralized treatment services, if multiple small NICUs 
are in close proximity, may increase access to laser treatment 
and ophthalmologists skilled in the treatment of ROP, so 
improving the quality of treatment (60).
Identification and Care of Visually Impaired Survivors
In view of the risk of visual impairment from a range of condi-
tions, including ROP, there has been debate in some countries 
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whether preterm babies should be routinely screened for visual 
impairment during childhood, even if they were not affected 
by ROP (7). Routine screening is not currently carried out in 
many settings, and increasing awareness among parents and 
teachers of the increased risk—and encouraging vision test-
ing if they have concerns—is important in all settings. Prompt 
treatment of strabismus and high refractive errors is required 
to prevent amblyopia and to promote normal development. 
Spectacles present a simple and affordable method of treating 
refractive errors associated with preterm birth but require fit-
ting and long-term follow-up so that the prescription can be 
changed as the child grows; moreover, repairing or replacing 
broken or lost spectacles also is essential (66). As blindness is 
associated with poor educational achievement, social isola-
tion, and poverty, particularly in LMICs (67), children with 
profound vision loss will also require assessment in low vision 
services, access to assistive devices, and appropriate placement 
and support in school to improve their independence and 
quality of life, and ensure a productive adulthood (66).
Conclusion
More than 30,000 preterm babies worldwide in 2010 are esti-
mated to be visually impaired due to ROP. Much of this burden 
is preventable with improved quality of neonatal care, nota-
bly oxygen monitoring, and with screening and treatment of 
vision-threatening ROP. Urgent action is required to improve 
awareness of ROP among all involved in the care of preterm 
babies, coupled with commitments to improve neonatal care, 
and to develop and implement national guidelines for the pre-
vention, detection, and treatment of ROP.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at http://
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